HILLSBORO, ORE. — Genentech, a member of Swiss pharmaceutical company Roche Group, plans to invest $750 million in a new manufacturing facility at its 75-acre campus in Hillsboro. The development will bring new end-to-end device filling capabilities to the site and expand Genentech’s capacity to support its future pipeline of innovative medicines.
The new facility will support the manufacturing of advanced drug delivery devices, such as pre-filled syringes and auto injectors. Designed for flexibility, the facility will be capable of both high- and low-volume device filling across a broad range of Genentech’s portfolio, enabling the site to respond to changing manufacturing needs as the company’s portfolio evolves.
Established in 2006, the Hillsboro campus is a hub for Genentech’s U.S. manufacturing network, supporting production across a broad range of therapeutic areas, including oncology, immunology and neurology. Roche and Genentech’s current U.S. footprint includes 13 manufacturing sites, 15 research and development sites and approximately 25,000 employees across 24 locations in eight states.